Is Neomycin + Polymyxin b + Prednisolone registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Neomycin + Polymyxin b + Prednisolone, including NEOPRED - P (10000,5,5 mg/ml,IU,mg/ml, Eye drops, suspension, SAR 10.45).

Is Neomycin + Polymyxin b + Prednisolone approved by the US FDA?

Drugs@FDA lists 1 application product line for Neomycin + Polymyxin b + Prednisolone, including POLY-PRED (Discontinued).

Active substances

Neomycin + Polymyxin b + Prednisolone

SFDA 2
US FDA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
NEOPRED - P	10000,5,5 mg/ml,IU,mg/ml	Eye drops, suspension · Ophthalmic use	1 Dropper Container	SAR 10.45	Generic · Prescription	Amman Pharmaceutical Industries (API)	Valid
PREDMYCIN-P EYE DROPS		Eye drops · Ocular use	1 Dropper Container	SAR 13.95	NCE · Prescription	ALLERGAN PHARMACEUTICALS LTD	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
POLY-PRED	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	suspension/drops · ophthalmic	ALLERGAN	Discontinued	10 May 1963

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.